<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587858</url>
  </required_header>
  <id_info>
    <org_study_id>10832</org_study_id>
    <nct_id>NCT02587858</nct_id>
  </id_info>
  <brief_title>NBIAready: Online Collection of Natural History Patient-reported Outcome Measures</brief_title>
  <official_title>NBIAready: Online Collection of Natural History Patient-reported Outcome Measures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan J. Hayflick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about Neurodegeneration with Brain Iron&#xD;
      Accumulation (NBIA) Disorders. Data is being collected on three types of NBIA disorders:&#xD;
&#xD;
      Pantothenate Kinase-Associated Neurodegeneration (PKAN), PLA2G6-associated Neurodegeneration&#xD;
      (PLAN) and Beta-propeller Protein-associated Neurodegeneration (BPAN). The study will (1)&#xD;
      collect information about how symptoms and findings in NBIA change over time and (2) identify&#xD;
      measures of NBIA that can be used in future clinical trials. Participants will follow links&#xD;
      to a secure website every 6 months for a period of 5-10 years to electronically complete a&#xD;
      set of rating scales as related to their NBIA disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Document the natural history of NBIA and identify new markers of disease progression.</measure>
    <time_frame>5-10 years</time_frame>
    <description>The unit of analyses will be the data collected on NBIA milestones and patient-reported outcome measures. Latent Growth Curve (LGC) modeling will be used to characterize the natural history of NBIA. If data support that certain disease milestones occur in a consistent order, or at consistent ages, then these data points will be candidate markers of disease progression. LGC will be used to characterize the natural history of NBIA and identify areas in which individuals with NBIA differ from the general population.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neurodegeneration With Brain Iron Accumulation (NBIA)</condition>
  <arm_group>
    <arm_group_label>PKAN</arm_group_label>
    <description>This group consists of individuals diagnosed with PKAN using a combination of MRI, other clinical findings, and PANK2 gene sequencing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLAN</arm_group_label>
    <description>This group consists of individuals diagnosed with PLAN using a combination of MRI, other clinical findings and PLA2G6 gene sequencing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPAN</arm_group_label>
    <description>This group consists of individuals diagnosed with BPAN using a combinatino of MRI, other clinical findings, and WDR45 gene sequencing.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      BPAN participants will be asked for blood and saliva samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The PKAN group consists of international individuals diagnosed with PKAN. The PLAN group&#xD;
        consists of international individuals diagnosed with PLAN. The BPAN group consists of&#xD;
        international individuals diagnosed with BPAN.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PKAN, PLAN or BPAN confirmed by gene testing and/or clinical features.&#xD;
&#xD;
          -  Ability to access a computer with internet services or a phone approximately once&#xD;
             every 6 months for up to 10 years to enter data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals who are not fluent in reading and communicating in English.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan J Hayflick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alison C Freed, BA</last_name>
    <phone>503 494 6838</phone>
    <email>freeal@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allison M Gregory, MS, CGC</last_name>
    <phone>503 494 4344</phone>
    <email>gregorya@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison C Freed, BA</last_name>
      <phone>503-494-6838</phone>
      <email>freeal@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Allison M Gregory, MS, CGC</last_name>
      <phone>503 494 4344</phone>
      <email>gregorya@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susan J Hayflick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nbiacure.org</url>
    <description>Official website of the OHSU NBIA research group</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Susan J. Hayflick</investigator_full_name>
    <investigator_title>Professor &amp; Chair, Molecular &amp; Medical Genetics</investigator_title>
  </responsible_party>
  <keyword>NBIA</keyword>
  <keyword>PKAN</keyword>
  <keyword>brain iron</keyword>
  <keyword>Neurodegeneration with Brain Iron Accumulation</keyword>
  <keyword>Hallervorden Spatz Syndrome</keyword>
  <keyword>Pantothenate Kinase Associated Neurodegeneration</keyword>
  <keyword>PLAN</keyword>
  <keyword>INAD</keyword>
  <keyword>PLA2G6-associated neurodegeneration</keyword>
  <keyword>BPAN</keyword>
  <keyword>Beta-propeller Protein-associated neurodegenration</keyword>
  <keyword>WDR45</keyword>
  <keyword>PLA2G6</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

